Last reviewed · How we verify
SCH 530348
At a glance
| Generic name | SCH 530348 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Vorapaxar on Thrombin Generation and Coagulability (PHASE4)
- Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor (PHASE4)
- Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus (PHASE4)
- Vorapaxar in the Human Endotoxemia Model (PHASE4)
- Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints (PHASE1, PHASE2)
- Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access (PHASE2)
- Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017) (PHASE2)
- Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCH 530348 CI brief — competitive landscape report
- SCH 530348 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI